Ionis Pharmaceuticals (IONS) Raw Materials (2009 - 2025)

Ionis Pharmaceuticals' Raw Materials history runs 17 years deep, the most recent figure standing at $640000.0 for Q1 2025.

• On a quarterly basis, Raw Materials fell 97.34% year-over-year to $640000.0 in Q1 2025; TTM through Mar 2025 was $640000.0, a 97.34% decrease from a year earlier, with the FY2024 full-year figure at $5.6 million, up 207.02% from the prior year.
• Raw Materials slipped to $640000.0 in Q1 2025 per IONS's latest filing, from $5.6 million in the prior quarter.
• Across five years, Raw Materials topped out at $24.6 million in Q2 2024 and bottomed at $640000.0 in Q1 2025.
• The 5-year median for Raw Materials is $18.6 million (2021), against an average of $17.0 million.
• Across the five-year window, Raw Materials jumped 207.02% in 2024 and slumped 97.34% in 2025, its largest moves.
• Year by year, Raw Materials stood at $18.6 million in 2021, then climbed by 5.97% to $19.8 million in 2022, then plunged by 90.84% to $1.8 million in 2023, then soared by 207.02% to $5.6 million in 2024, then slumped by 88.48% to $640000.0 in 2025.
• Per Business Quant, the three latest IONS Raw Materials figures stand at $640000.0 (Q1 2025), $5.6 million (Q4 2024), and $21.7 million (Q3 2024).